+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gastroesophageal Reflux Pipeline Drugs and Companies, 2021- Phase, Mechanism of Action, Route, Licensing/Collaboration, Pre-clinical and Clinical Trials

  • PDF Icon


  • 70 Pages
  • November 2021
  • Region: Global
  • VPA Research
  • ID: 5463777
Gastroesophageal Reflux pipeline drugs and companies, 2021- Phase, Mechanism of Action, Route, Licensing/collaboration, pre-clinical and clinical trials

The global comprehensive report on “Gastroesophageal Reflux pipeline drugs and companies” presents key-decision makers with critical insights into Gastroesophageal Reflux pipeline data. It provides complete analysis on pipeline drugs detailing Phases, route of administration, mechanism of action, licensing and collaborations, clinical trial details including pre-clinical phase and clinical trials.

Gastroesophageal Reflux pipeline Drug Snapshot, 2021

The Gastroesophageal Reflux pipeline study analyzes and monitors the development landscape with the current status of each of the pipeline drugs under development for Gastroesophageal Reflux. In addition to recent status, overview of drugs is included in the study. Wide range of Gastroesophageal Reflux drug related details including of company, indication, country, current status, drug alternative names, originator, orphan drug status, fast track details and others are provided.

Gastroesophageal Reflux drug development pipeline by phase

The Gastroesophageal Reflux pipeline study monitors the progress of new drug programs and provides analysis of phases, covering drugs from discovery to launch including discovery stage, preclinical, phase 1, phase 2, phase 3, pre-registration and other phases. The drug development stage for all Gastroesophageal Reflux pipeline candidates is provided in the report enables you to understand timetable developments in Gastroesophageal Reflux therapeutic area.

Gastroesophageal Reflux pipeline drug Technology, Licensing and Collaboration Details

Details of technologies used for development of Gastroesophageal Reflux pipeline candidates, licensing and collaboration agreements, partnership and other announcements, regulatory approval and other details are included in the Gastroesophageal Reflux research study. Companies looking to partner with other players are also detailed in the report.

Gastroesophageal Reflux- mechanism of action of pipeline candidates

Gastroesophageal Reflux pipeline guide details the mechanism of action of each of the drug candidate under development. Further, leading types of mechanism of action (MoA) targeted by different Gastroesophageal Reflux companies are identified to support decision makers target the most potential drugs under development.

Further, route of administration including oral, topical, sub-cutaneous, IV, ophthalmic and others are provided to assist researchers to understand most sought and least sought route of Gastroesophageal Reflux drug administration.

Gastroesophageal Reflux Drugs- Preclinical and Clinical Trials

This chapter in Gastroesophageal Reflux preclinical and clinical trials assists in gaining clear understanding of the timetable developments in Gastroesophageal Reflux product area. Preclinical and clinical trial details of pipeline candidates for Gastroesophageal Reflux are detailed in the report. Details including participants, duration, companies, locations and others are provided for the trials.

Gastroesophageal Reflux companies and Profiles

Companies developing Gastroesophageal Reflux pipeline products are analyzed in the industry report, presenting details of business overview, location, and year of establishment, contacts, key employees, and a brief business profile.

Gastroesophageal Reflux Market Developments

The report presents the recent news and developments in the Gastroesophageal Reflux pipeline industry. Progress of candidates, mergers, acquisitions, asset transactions, licensing, collaborations, partnership and joint ventures, regulatory approvals, marketing and other relevant news and deals are discussed in the report.

Reasons to Buy

  • Make better-informed decisions based on the current status of each of the pipeline drug candidate
  • Identify new business opportunities by evaluating the progress of the Gastroesophageal Reflux R&D pipeline
  • Analyze the market and research segments based on a comprehensive analysis of Gastroesophageal Reflux pipeline drugs and clinical trials
  • Identify Gastroesophageal Reflux drug pipeline trends based on consistently delivered hands on pipeline and clinical trials information
  • Gain clear understanding of the Gastroesophageal Reflux drugs through our expert coverage and in-depth analysis of drugs, companies and market trends
  • Check the Gastroesophageal Reflux pipeline progress of target companies and key strategies of leading players
  • Gain real-time insights into the global Gastroesophageal Reflux pipeline news, developments and insights

Scope of the Report

  • Disease overview including Gastroesophageal Reflux symptoms, widely used treatment options, companies and other details are included
  • Gastroesophageal Reflux Pipeline Summary including the dominant phase type, number of drug candidates progressing to advanced phases, early stage pipeline candidates, leading companies, dominant route of mechanism and route of administration and other details are provided.
  • Gastroesophageal Reflux pipeline drug count by phase, company and mechanism of action
  • Gastroesophageal Reflux companies investing R&D resources in pipeline
  • Dominant Mechanism of Action
  • Most researched route of administration
  • For each pipeline candidate, drug, originator, co-developers, other companies, special status, phase, synonym, current status and other details are included
  • Clinical trial information for each Gastroesophageal Reflux pipeline candidate are provided including preclinical, phase 1, phase 2 and phase 3 details
  • Gastroesophageal Reflux companies including their business snapshot, business description and Gastroesophageal Reflux pipelines are included.
  • Recent Gastroesophageal Reflux market developments, pipeline news and deals are provided

Table of Contents

1. Table of Contents
1.1 List of Tables
1.2 List of Figures
2. Executive Summary
2.1 Gastroesophageal Reflux Disease overview
2.2 Companies investing in Gastroesophageal Reflux industry
3 Gastroesophageal Reflux Pipeline Snapshot, 2021
3.1 Gastroesophageal Reflux Pipeline Drugs- Dominant phase type
3.2 Gastroesophageal Reflux pipeline Drugs- Leading Mechanism of Action
3.3 Gastroesophageal Reflux Pipeline Drugs- Widely researched Route of Administration
3.4 Gastroesophageal Reflux Pipeline- New Molecular Entity
3.5 Gastroesophageal Reflux pipeline- Companies, Universities and Institutes
4. Gastroesophageal Reflux Drug Profiles
4.1 Current Status of Gastroesophageal Reflux Drug Candidates, 2021
4.2 Gastroesophageal Reflux Drugs in Development- Originator/Licensor
4.3 Gastroesophageal Reflux Drugs in Development- Route of Administration
4.4 Gastroesophageal Reflux Drugs in Development- New Molecular Entity (NME)
5. Gastroesophageal Reflux Clinical Trials
5.1 Preclinical Trial details
5.2 Phase 1 Clinical Trial Details
5.3 Phase 2 Clinical Trial Details
5.4 Phase 3 Clinical Trial Details
6. Gastroesophageal Reflux Companies and Universities
6.1 Leading Gastroesophageal Reflux companies researching in drug development
6.2 Leading Gastroesophageal Reflux Universities/Institutes investing in drug development
7. Gastroesophageal Reflux News and Deals
7.1 Recent Gastroesophageal Reflux Market Developments
7.2 Pipeline Drug News Updates
7.3 Pipeline Company updates
8. Appendix
8.1 Sources and Research Methodology
8.2 Online Database
8.3 Primary and Secondary Methodology
8.4 Customization options
8.5 Contact